(Q35876345)

10 August 2017

1 reference

title

Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection (English)

1 reference

10 August 2017

main subject

anti-retroviral agent

0 references

3

Caroline M Perry

1 reference

10 August 2017

2

Greg L Plosker

1 reference

10 August 2017

Therese M Chapman

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

18

1 reference

10 August 2017

page(s)

2101-2124

1 reference

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

10 August 2017

cites work

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir

1 reference

12 December 2020

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

1 reference

12 December 2020

Amprenavir: a review of its clinical potential in patients with HIV infection

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation

1 reference

12 December 2020

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 reference

12 December 2020

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

1 reference

12 December 2020

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers

1 reference

12 December 2020

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

Adherence to HAART Regimens

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-200464180-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1052401869

0 references

1 reference